JP2013523898A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523898A5
JP2013523898A5 JP2013505181A JP2013505181A JP2013523898A5 JP 2013523898 A5 JP2013523898 A5 JP 2013523898A5 JP 2013505181 A JP2013505181 A JP 2013505181A JP 2013505181 A JP2013505181 A JP 2013505181A JP 2013523898 A5 JP2013523898 A5 JP 2013523898A5
Authority
JP
Japan
Prior art keywords
infection
composition
composition according
bacterial
snag nanofibers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013505181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/032709 external-priority patent/WO2011130646A1/en
Publication of JP2013523898A publication Critical patent/JP2013523898A/ja
Publication of JP2013523898A5 publication Critical patent/JP2013523898A5/ja
Withdrawn legal-status Critical Current

Links

JP2013505181A 2010-04-15 2011-04-15 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用 Withdrawn JP2013523898A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32465710P 2010-04-15 2010-04-15
US61/324,657 2010-04-15
PCT/US2011/032709 WO2011130646A1 (en) 2010-04-15 2011-04-15 Anti-bacterial applications of poly -n-acetylglucosamine nanofibers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016095328A Division JP6400628B2 (ja) 2010-04-15 2016-05-11 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用

Publications (2)

Publication Number Publication Date
JP2013523898A JP2013523898A (ja) 2013-06-17
JP2013523898A5 true JP2013523898A5 (enExample) 2014-06-05

Family

ID=44799052

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013505181A Withdrawn JP2013523898A (ja) 2010-04-15 2011-04-15 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP2016095328A Active JP6400628B2 (ja) 2010-04-15 2016-05-11 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP2018166053A Expired - Fee Related JP6761453B2 (ja) 2010-04-15 2018-09-05 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016095328A Active JP6400628B2 (ja) 2010-04-15 2016-05-11 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
JP2018166053A Expired - Fee Related JP6761453B2 (ja) 2010-04-15 2018-09-05 ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用

Country Status (12)

Country Link
US (5) US8858964B2 (enExample)
EP (1) EP2563371A4 (enExample)
JP (3) JP2013523898A (enExample)
KR (1) KR101883797B1 (enExample)
CN (2) CN103108638B (enExample)
AU (1) AU2011239466B2 (enExample)
BR (1) BR112012025844A2 (enExample)
CA (1) CA2796068C (enExample)
IL (1) IL222375A (enExample)
MX (1) MX342912B (enExample)
NZ (2) NZ602909A (enExample)
WO (1) WO2011130646A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552842T3 (es) 2007-02-19 2015-12-02 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
KR101883797B1 (ko) 2010-04-15 2018-08-30 마린 폴리머 테크놀로지스, 인코퍼레이션. 폴리-ｎ-아세틸글루코사민 나노섬유의 항-세균성 용도
EP3501284A1 (en) 2011-04-15 2019-06-26 Marine Polymer Technologies, Inc. Treatment of skin deseases with poly-n-acetyl glucosamine nanofibers
CA2850366A1 (en) * 2011-09-30 2013-04-04 The Research Institute At Nationwide Children's Hospital Compositions and methods for detection of defensins in a patient sample
MX2014014067A (es) * 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
WO2013192157A1 (en) * 2012-06-18 2013-12-27 Duke University Non-human model for wound healing
JP6243443B2 (ja) * 2012-12-20 2017-12-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 全身健康状態の尺度としてのパターン認識受容体の発現
EP3494791B1 (en) 2013-03-14 2023-03-01 Marine Polymer Technologies, Inc. Treatment of skin-related symptoms of ehlers-danlos syndrome with poly-n-acetylglucosamine nanofibers
JP2015048436A (ja) * 2013-09-03 2015-03-16 公立大学法人福井県立大学 植物の耐病性を向上させる、生物由来キチン質含有物、その使用方法、及びその製造方法
EP3034612A1 (en) 2014-12-16 2016-06-22 Greenaltech, S.L. Chitin and chitosan producing methods
US10500222B2 (en) * 2015-10-19 2019-12-10 Wayne State University Compositions and methods relating to treatment of infection
CN107460140B (zh) * 2016-06-02 2020-11-13 浙江科技学院 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法
WO2019046577A1 (en) 2017-08-31 2019-03-07 Syngulon Sa METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES
US20210169922A1 (en) * 2018-05-11 2021-06-10 Marine Polymer Technologies, Inc. Use of poly-n-acetylglucosamine nanofibers for the treatment of gingival recession
BR102021021376A2 (pt) * 2021-10-25 2023-05-09 União Brasileira De Educação Católica - Ubec Composição, processo de produção da composição e uso da composição de nanofibras que compreende pva, quitosana, antibiótico e peptídeo de defesa do hospedeiro
IT202200004574A1 (it) 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni
KR102846669B1 (ko) * 2022-04-14 2025-08-13 충남대학교산학협력단 miRNA 24가 봉입된 키토산 나노입자를 유효성분으로 포함하는 에드워드시엘라 피스시시다에 대한 어류용 항생 조성물
CN115671368B (zh) * 2022-10-28 2024-03-22 东华大学 一种用于生物膜清除的纳米纤维复合贴片及其制备方法

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3989535A (en) 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US3988411A (en) 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
US4068757A (en) 1976-11-03 1978-01-17 American Cyanamid Company Chitin derived powder in sterile surgical element package
US4195175A (en) 1978-01-03 1980-03-25 Johnson Edwin L Process for the manufacture of chitosan
JPS55152705A (en) 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
US4378017A (en) 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS56131639A (en) 1980-03-21 1981-10-15 Kureha Chem Ind Co Ltd Protein-chitosan composition
JPS56133344A (en) 1980-03-21 1981-10-19 Kureha Chem Ind Co Ltd Novel composite material
US4532134A (en) 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US4394373A (en) 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4470397A (en) 1981-11-11 1984-09-11 Lucas Industries Public Limited Company Fuel injection pumping apparatus
US4605623A (en) 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
JPS5998660A (ja) 1982-11-26 1984-06-07 House Food Ind Co Ltd 麺類の乾燥方法
JPS59156770A (ja) 1983-02-25 1984-09-06 Canon Inc インパクト型プリンタ
JPS58220899A (ja) 1983-03-22 1983-12-22 工業技術院長 キチン系抄造体の製造方法
JPS6025003A (ja) 1983-07-20 1985-02-07 Shiro Okamura 光磁気記録装置
US4803168A (en) 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPS60208302A (ja) 1984-03-31 1985-10-19 Unitika Ltd キチン成形体の製造方法
JPS60215003A (ja) 1984-04-10 1985-10-28 Unitika Ltd キトサン成形体の製造方法
DE3583263D1 (de) 1984-08-03 1991-07-25 Unitika Ltd Geformte gegenstaende aus chitin.
JPH0611810B2 (ja) 1984-08-23 1994-02-16 ユニチカ株式会社 多孔性キチン成形体及びその製造方法
JPS61253065A (ja) 1985-05-02 1986-11-10 片倉チツカリン株式会社 キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
JPS62288602A (ja) 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
JPH0776241B2 (ja) 1986-06-06 1995-08-16 ユニオン、カーバイド、コーポレーション アミノ多糖類及びそれらの誘導体の酸による非晶出化方法
JPH0441422Y2 (enExample) 1986-10-17 1992-09-29
JPH0525289Y2 (enExample) 1987-01-21 1993-06-25
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4942129A (en) 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0532702Y2 (enExample) 1987-10-09 1993-08-20
JP2560363B2 (ja) 1987-12-23 1996-12-04 ライオン株式会社 キチン又はキトサン類の精製法
EP0330106A1 (de) 1988-02-25 1989-08-30 Akzo Nobel N.V. Modifizierte Cellulose für biocompatible Dialysemembranen II und Verfahren zu deren Herstellung
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5008116A (en) 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
DE3903797A1 (de) 1989-02-09 1990-08-16 Hoechst Ag Verfahren zur herstellung von aktivierten chitosanen und deren verwendung bei der herstellung von chitosanderivaten
JPH0657761B2 (ja) 1989-02-27 1994-08-03 富士紡績株式会社 多孔質キトサン成形物の製造法
JPH02240101A (ja) 1989-03-14 1990-09-25 Lion Corp 硫酸化キトサン誘導体及びその製造方法
EP0390481B1 (en) 1989-03-23 1996-02-28 Sanyo Chemical Industries Ltd. Surgical adhesive sheet
IT1229167B (it) 1989-04-10 1991-07-22 Texcontor Ets Complessi del ferro o di altri metalli con derivati solfonati del chitosano
US5071977A (en) 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
AU5885690A (en) 1989-07-11 1991-01-17 Union Carbide Chemicals And Plastics Company Inc. Emulsions comprising aminopolysaccharides
US5116747A (en) 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
IL96101A0 (en) 1989-10-31 1991-07-18 Pfizer Hospital Prod Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
JPH064531B2 (ja) 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
US5463022A (en) 1990-08-17 1995-10-31 Drug Delivery System Institute, Ltd. N-acetylcarboxymethylchitosan derivatives and process for preparation thereof
DE69124983T2 (de) 1990-08-30 1997-10-16 Warner-Lambert Co., Morris Plains, N.J. Formteile aus einer thermoplastischen stärkeschmelze
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04126701U (ja) 1991-05-13 1992-11-18 株式会社日立製作所 潤滑機能を有する下部軸受
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JPH0691819B2 (ja) 1991-05-27 1994-11-16 工業技術院長 デアセチラーゼの製造方法
JP3046099B2 (ja) 1991-06-19 2000-05-29 ユニチカ株式会社 キチン又はキトサンの綿状物
CA2072395A1 (en) 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
JPH0525289A (ja) 1991-07-19 1993-02-02 Unitika Ltd キチン成形体の製造法
JPH0532702A (ja) 1991-08-01 1993-02-09 Unitika Ltd 細胞接着性キチン
JPH0551465A (ja) 1991-08-23 1993-03-02 Unitika Ltd 球状キチンの製造方法
US5219749A (en) 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
US5229123A (en) 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
BR9206722A (pt) 1991-11-05 1995-07-18 Smithkline Beecham Corp Antagonista receptores de endotelina
IL100096A (en) 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
DE4200080A1 (de) 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
JPH05235905A (ja) 1992-02-21 1993-09-10 Toshiba Corp Ｃｒｃ演算装置
JPH076126A (ja) 1992-02-26 1995-01-10 Nec Corp プロセッサ間バス伝送方式
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
JPH05271094A (ja) 1992-03-26 1993-10-19 Fuji Photo Film Co Ltd カルボキシメチル化キチン誘導体を用いる癌転移抑制剤
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
US5871985A (en) 1992-09-28 1999-02-16 Brown University Research Foundation Particulate non cross-linked chitosan core matrices for encapsulated cells
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5447505A (en) 1993-08-04 1995-09-05 Merocel Corporation Wound treatment method
JPH07102458A (ja) 1993-09-30 1995-04-18 Unitika Ltd キチンウェブ状物
US5846952A (en) 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US5622834A (en) 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
AU5917896A (en) 1995-06-06 1996-12-24 Marine Polymer Technologies, Inc. Poly-beta-1-4-N-acetylglucosamine
FR2736835B1 (fr) 1995-07-17 1997-10-10 Aber Technologies Pansement pour plaies chroniques, notamment escarres, en gel de chitine
AU6603996A (en) 1995-08-24 1997-03-19 Warner-Lambert Company Furanone endothelin antagonists
AU2529297A (en) 1996-04-10 1997-10-29 Warner-Lambert Company Ketoacid endothelin antagonists
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6162241A (en) 1997-08-06 2000-12-19 Focal, Inc. Hemostatic tissue sealants
ES2221696T3 (es) 1997-08-19 2005-01-01 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de piridinas 2,5.disustituidas.
CA2234936C (en) 1998-04-17 2004-06-29 Glucogenics Pharmaceuticals Inc. Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
US6046179A (en) 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
DE19821598A1 (de) 1998-05-14 1999-11-18 Henkel Kgaa Verfahren zum Abbau von Biopolymeren
TW585762B (en) 1999-11-11 2004-05-01 Tanabe Seiyaku Co Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US8741335B2 (en) 2002-06-14 2014-06-03 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan
US7371403B2 (en) 2002-06-14 2008-05-13 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
JP2003128704A (ja) 2001-10-24 2003-05-08 Matsumoto Shika Univ キチン・キトサンの低分子化方法及び骨伝導物の製造方法
GB0126923D0 (en) 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
WO2003041697A1 (en) 2001-11-14 2003-05-22 Ralph Ryback Method for treating autoimmune diseases
JP3947391B2 (ja) * 2001-11-28 2007-07-18 独立行政法人 日本原子力研究開発機構 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法
US20090130186A1 (en) * 2002-06-14 2009-05-21 Hemcon Medical Technologies, Inc. Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles
US7037983B2 (en) 2002-06-14 2006-05-02 Kimberly-Clark Worldwide, Inc. Methods of making functional biodegradable polymers
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
WO2004024196A1 (en) 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Wound dressings for the treatment of wound infection
GB2393120A (en) 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
US20070237812A1 (en) 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
AU2003303522B2 (en) 2002-12-31 2009-05-28 Marine Polymer Technologies, Inc. Hemostatic compositions and uses therefor
JP5028086B2 (ja) 2003-02-24 2012-09-19 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞−ポリマー繊維組成物及びその使用
JP2007504918A (ja) 2003-09-12 2007-03-08 マリン ポリマー テクノロジーズ，インコーポレーテッド 血液透析患者における血管アクセスの保存
EP1671629A4 (en) 2003-09-19 2008-11-26 Otsuka Pharma Co Ltd HUMAN BETA DEFENSIN SECRETION AMPLIFIER
RU2240830C1 (ru) 2003-12-26 2004-11-27 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов Раневое покрытие и способ его получения
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US7704522B2 (en) 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
CA2487564A1 (en) 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
DE102004061406A1 (de) 2004-12-21 2006-07-06 Bayer Innovation Gmbh Infektionsresistente Polyurethanschäume, Verfahren zu ihrer Herstellung und Verwendung in antiseptisch ausgestatteten Wundauflagen
US20070036846A1 (en) * 2005-08-15 2007-02-15 Tsang Wing W M Wound dressing and method of manufacture thereof
US20090075383A1 (en) 2005-11-04 2009-03-19 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
US8277849B2 (en) 2006-01-19 2012-10-02 Solazyme, Inc. Microalgae-derived compositions for improving the health and appearance of skin
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2008039390A2 (en) 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
WO2008048076A1 (en) 2006-10-20 2008-04-24 Amorepacific Corporation A composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
KR100882611B1 (ko) 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
BRPI0807065A2 (pt) 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
ES2552842T3 (es) 2007-02-19 2015-12-02 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
US8436157B2 (en) 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
NZ590466A (en) 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins
US20100086613A1 (en) 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
KR101883797B1 (ko) 2010-04-15 2018-08-30 마린 폴리머 테크놀로지스, 인코퍼레이션. 폴리-ｎ-아세틸글루코사민 나노섬유의 항-세균성 용도
WO2011140638A1 (en) 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
CN103282024A (zh) 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法
EP3501284A1 (en) 2011-04-15 2019-06-26 Marine Polymer Technologies, Inc. Treatment of skin deseases with poly-n-acetyl glucosamine nanofibers
WO2013038776A1 (ja) 2011-09-15 2013-03-21 国立大学法人鳥取大学 炎症性腸疾患治療剤
EP3494791B1 (en) 2013-03-14 2023-03-01 Marine Polymer Technologies, Inc. Treatment of skin-related symptoms of ehlers-danlos syndrome with poly-n-acetylglucosamine nanofibers

Similar Documents

Publication Publication Date Title
JP2013523898A5 (enExample)
JP2018203766A5 (enExample)
Noori et al. The effect of magnesium oxide nanoparticles on the antibacterial and antibiofilm properties of glass-ionomer cement
Gottlieb et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis
Suwantarat et al. High prevalence of reduced chlorhexidine susceptibility in organisms causing central line–associated bloodstream infections
Neu Clinical microbiology of azithromycin
Chen et al. Ethanol extract of Sanguisorba officinalis L. inhibits biofilm formation of methicillin-resistant Staphylococcus aureus in an ica-dependent manner
KR101883797B1 (ko) 폴리-ｎ-아세틸글루코사민 나노섬유의 항-세균성 용도
Samson et al. Long-term effects of azithromycin in patients with cystic fibrosis
US9724295B2 (en) Compositions for topical treatment of microbial infections
Wilson et al. Advanced endotracheal tube biofilm stage, not duration of intubation, is related to pneumonia
WO2015077794A4 (en) Synergistic bacterial compositions and methods of production and use thereof
JP2011530534A5 (enExample)
Zawadzki et al. Identification of infectious microbiota from oral cavity environment of various population group patients as a preventive approach to human health risk factors
Gottaslo et al. Effects of oxygen on in-vitro biofilm formation and antimicrobial resistance of Pseudomonas aeruginosae
Zahmatkesh et al. Effect of samarium oxide nanoparticles on virulence factors and motility of multi-drug resistant Pseudomonas aeruginosa
Londoñe-Bailon et al. In vitro antibacterial, antioxidant and cytotoxic activity of methanol-acetone extracts from Antarctic lichens (Usnea antarctica and Usnea aurantiaco-atra)
Moskovicz et al. Skin microbiota dynamics following B. subtilis formulation challenge: an in vivo study in mice
Hamad et al. Outcomes in lung transplant recipients with Mycobacterium abscessus infection: a 15-year experience from a large tertiary care center
De Breij et al. The licorice pentacyclic triterpenoid component 18β-glycyrrhetinic acid enhances the activity of antibiotics against strains of methicillin-resistant Staphylococcus aureus
Bakkiyaraj et al. Anti-biofilm properties of a mupirocin spray formulation against Escherichia coli wound infections
WO2012007913A3 (en) Oral administration forms for controlled release of rifampicin or other antibiotics for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract
Singh et al. Autophagy genes of host responds to disruption of gut microbial community by antibiotics
Singh et al. Therapeutical effect of extracts of Terminalia chebula in inhibiting human pathogens and free radicals
Fabre et al. Catheter-related bloodstream infection due to biofilm-producing Capnocytophaga sputigena